Targeted CTLA-4 Inhibition in Squamous NSCLC

In this segment, the panel explores the rationale for selectively targeting CTLA-4 within the tumor microenvironment in advanced squamous non-small cell lung cancer (NSCLC), with particular attention to intratumoral regulatory T cells (Tregs) and the potential to improve antitumor activity while limiting systemic toxicity. The experts discuss whether preferential activity against intratumoral Tregs could provide a more focused approach to CTLA-4 inhibition and potentially create a wider therapeutic window. Dr. Edward Kim describes the concept as an important hypothesis while emphasizing that the relative contributions of target localization, duration of suppression, and other biological factors remain uncertain. The panel also considers parallels with the evolution of antibody-drug conjugates (ADCs), including the potential for future payloads with immunomodulatory rather than primarily cytotoxic effects. Dr. Narjust Florez highlights the broader tumor microenvironment and the potential influence of factors such as treatment, tumor characteristics, and genomic signatures. Dr. Christian Rolfo concludes that although the mechanism and early evidence are compelling, further clinical data are needed to validate these approaches.